2388-32-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloroquinoline-4-carbonyl chloride is used as a reagent for the synthesis of complex molecules, which are essential in the development of new pharmaceutical products. Its unique structure allows for the creation of a wide range of compounds with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, 2-Chloroquinoline-4-carbonyl chloride is used as a reagent in the synthesis of various complex molecules, contributing to the production of specialty chemicals and materials with diverse applications. Its versatility in chemical reactions makes it a valuable component in the synthesis process.

InChI:InChI=1/C10H5Cl2NO/c11-9-5-7(10(12)14)6-3-1-2-4-8(6)13-9/h1-5H

Upstream product

• 15733-89-8 2-hydroxyquinoline-4-carboxylic acid 
• 5467-57-2 2-chloroquinoline-4-carboxylic acid 
• 15733-89-8 2-quinolone-4-carboxylic acid 
• 91-56-5 indole-2,3-dione 

Downstream Products

• 861020-37-3 1-(2-chloro-quinoline-4-carbonyl)-4-phenyl-piperazine 
• 107779-36-2 2-(n-butyloxy)-4-(n-butyloxycarbonyl)-quinoline 
• 87864-14-0 2-chloro-quinoline-4-carboxylic acid-(2-diethylamino-ethylamide) 
• 135323-86-3 2-chloro-quinoline-4-carboxylic acid phenyl-amide 
• 135323-90-9 2-chloro-quinoline-4-carboxylic acid benzyl-amide 
• 39112-22-6 2-chloro-4-benzoylquinoline 
• 4295-16-3 2-chloroquinoline-4-carboxamide 
• 135323-89-6 2-Chloro-quinoline-4-carboxylic acid (4-methoxy-phenyl)-amide 
• 588694-56-8 2-chloro-quinoline-4-carboxylic acid p-tolyl ester 
• 356084-48-5 2-chloro-quinoline-4-carboxylic acid 4-bromo-phenyl ester 
• 588694-59-1 2-chloro-quinoline-4-carboxylic acid 4-methoxy-phenyl ester 
• 356084-70-3 2-chloro-quinoline-4-carboxylic acid 4-acetyl-phenyl ester 
• 5467-61-8 ethyl ester of 2-chlorocinchoninic acid 
• 875585-54-9 N-benzyl-2-chloro-N-methylquinoline-4-carboxamide 

Relevant academic research and scientific papers

Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study

Enterovirus A71 (EV-A71) is a human pathogen causing hand, foot and mouth disease (HFMD) which seriously threatened the safety and lives of infants and young children. However, there are no licensed direct antiviral agents to cure the HFMD. In this study, a series of quinoline formamide analogues as effective enterovirus inhibitors were developed, subsequent systematic structure-activity relationship (SAR) studies demonstrated that these quinoline formamide analogues exhibited good potency to treat EV-A71 infection. As described, the most efficient EV-A71 inhibitor 6i showed good anti-EV-A71 activity (EC50 = 1.238 μM) in RD cells. Furthermore, compound 6i could effectively prevent death of virus infected mice at dose of 6 mg/kg. When combined with emetine (0.1 mg/kg), this treatment could completely prevent the clinical symptoms and death of virus infected mice. Mechanism study indicated that compound 6i inhibited EV-A71 via targeting 2C helicase, thus impeding RNA remodeling and metabolism. Taken together, these data indicated that 6i is a promising EV-A71 inhibitor and worth extensive preclinical investigation as a lead compound.

Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity

A series of novel quinoline-chalcone derivatives were designed, synthesized, and evaluated for their antiproliferative activity. Among them, compound 24d exhibited the most potent activity with IC50 values ranging from 0.009 to 0.016 μM in a panel of cancer cell lines. Compound 24d also displayed a good safety profile with an LD50 value of 665.62 mg/kg by intravenous injection, and its hydrochloride salt 24d-HCl significantly inhibited tumor growth in H22 xenograft models without observable toxic effects, which was more potent than that of CA-4. Mechanism studies demonstrated that 24d bound to the colchicine site of tubulin, arrested the cell cycle at the G2/M phase, induced apoptosis, depolarized mitochondria, and induced reactive oxidative stress generation in K562 cells. Moreover, 24d has potent in vitro antimetastasis and in vitro and in vivo antivascular activities. Collectively, our findings suggest that 24d deserves to be further investigated as a potent and safe antitumor agent for cancer therapy.

Method for preparing N-(2-(diethyl)aminoethyl)-2-chloro-4-quinolinecarboxamide

The invention discloses a method for preparing a dibucaine hydrochloride intermediate N-(2-(diethyl)aminoethyl)-2-chloro-4-quinolinecarboxamide by a one-pot method. The method comprises the followingsteps: using 2-hydroxy-4-carboxyquinoline and thionyl chloride to synthesize 2-chloroquinoline-4-formyl chloride under catalysis of DMF; concentrating a reaction liquid to dry; and directly reacting the product with N,N'-diethylethylenediamine under conditions of an acid binding agent to obtain N-(2-(diethyl)aminoethyl)-2-chloro-4-quinolinecarboxamide having a liquid phase purity of 99.9% or aboveand a yield of 93% or above. The method for preparing N-(2-(diethyl)aminoethyl)-2-chloro-4-quinolinecarboxamide has advantages of short production cycle, simple operation, low cost, high yield and high quality, and is conducive to industrial production.

Quinoline formamide compound and preparation method thereof and application of anti-enterovirus type 71

The invention discloses a quinoline formamide compound and a preparation method thereof and an application of an anti-enterovirus type 71 (EV71), and belongs to the technical field of medicine. Specifically, 2-chloroquinoline-4-formamide derivative and an alcohol compound are subjected to a substitution reaction, so that a series of quinoline formamide compounds are prepared. The quinoline formamide compounds have the activity of resisting enterovirus type 71, have small toxicity to cells, can be developed as a new anti-EV 71 drug, and have a wide application prospect.

ANTI-MALARIAL AGENTS

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents

A series of fused and functionalized pyridine derivatives were designed, synthesized and tested for their potential antitubercular properties. All these novel compounds were prepared by using multistep methods involving the construction of pyridine ring as a key synthetic step. Some of these compounds were found to be interesting when tested for their antitubercular properties in vitro and one of them appeared as an attractive and potential antitubercular agent.

Identification of a new series of STAT3 inhibitors by virtual screening

The signal transducer and activator of transcription 3 (STAT3) is considered to be an attractive therapeutic target for oncology drug development. We identified a N-[2-(1,3,4-oxadiazolyl)]-4-quinolinecarboxamide derivative, STX-0119, as a novel STAT3 dimerization inhibitor by a virtual screen using a customized version of the DOCK4 program with the crystal structure of STAT3. In addition, we used in vitro cell-based assays such as the luciferase reporter gene assay and the fluorescence resonance energy transfer-based STAT3 dimerization assay. STX-0119 selectively abrogated the DNA binding activity of STAT3 and suppressed the expression of STAT3-regulated oncoproteins such as c-myc and survivin in cancer cells. In contrast, a truncated inactive analogue, STX-0872, did not exhibit those activities. Oral administration of STX-0119 effectively abrogated the growth of human lymphoma cells in a SCC-3 subcutaneous xenograft model without visible toxicity. Structure-activity relationships of STX-0119 derivatives were investigated using the docking model of the STAT3-SH2 domain/STX-0119.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Synthesis and anti-tuberculosis activity of 2,4-disubstituted quinolines

Synthesis and anti-tuberculosis activity of a new series of 2,4-disubstituted quinolines have been reported. The most promising compounds have been found to exhibit 99% inhibition at 6.25 ng/mL against drug-sensitive M. tuberculosis H37Rv strain and >90% inhibition at 12.5 ng/mL against isoniazid resistant TB strain.

AMINOPYRROLIDINE COMPOUND

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.